Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The underlying goal of this study is to assess 123-I IBVM SPECT imaging as a tool to assess
cholinergic transporter binding in the brain of AD and PD research participants and age- and
gender-matched healthy subjects.